Quoin Pharmaceuticals LT-ADRQNRX
13F holders, Q3 2025 (September 30)4holders −2
0new positions
2sold out
$7.19avg. 13F price*
At the end of Q3 2025, 4 institutions reported holding Quoin Pharmaceuticals LT-ADR (QNRX) in their 13F filings, down 2 from Q2 2025. 0 opened new positions and 2 sold out. The largest holders were Rhumbline Advisers ($9K), GAMMA Investing LLC ($2K) and SBI Securities Co., Ltd. ($14).
- Company
- Quoin Pharmaceuticals LT-ADR
- CUSIP
- 74907L409
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $9K |
All 13F filers, Q2 2025 → Q3 2025: 38 shares bought and 1,084 shares sold, net −1,046 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Rhumbline Advisers | 0.00% | Reduce -2.6% | 1,210 | $9K |
| GAMMA Investing LLC | 0.00% | Add +15.8% | 278 | $2K |
| SBI Securities Co., Ltd. | 0.00% | No change | 2 | $14 |
| UBS Group AG | 0.00% | Reduce -99.2% | 1 | $7 |
"% of holder's portfolio" is QNRX's weight in each manager's 13F, not the share of Quoin Pharmaceuticals LT-ADR the manager owns.